These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 14507240)

  • 1. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
    Rajkumar T; Soumittra N; Nancy NK; Swaminathan R; Sridevi V; Shanta V
    Asian Pac J Cancer Prev; 2003; 4(3):203-8. PubMed ID: 14507240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
    Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR;
    Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
    Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
    Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
    Vaidyanathan K; Lakhotia S; Ravishankar HM; Tabassum U; Mukherjee G; Somasundaram K
    J Biosci; 2009 Sep; 34(3):415-22. PubMed ID: 19805903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
    Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
    BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited relevance of the CHEK2 gene in hereditary breast cancer.
    Dufault MR; Betz B; Wappenschmidt B; Hofmann W; Bandick K; Golla A; Pietschmann A; Nestle-Krämling C; Rhiem K; Hüttner C; von Lindern C; Dall P; Kiechle M; Untch M; Jonat W; Meindl A; Scherneck S; Niederacher D; Schmutzler RK; Arnold N
    Int J Cancer; 2004 Jun; 110(3):320-5. PubMed ID: 15095295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
    Skasko E; Kluska A; Niwińska A; Kwiatkowska E; Bałabas A; Piatkowska M; Dabrowska M; Nowakowska D; Pieńkowski T
    Onkologie; 2009 Apr; 32(4):182-8. PubMed ID: 19372713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
    Manoukian S; Peissel B; Frigerio S; Lecis D; Bartkova J; Roversi G; Radice P; Bartek J; Delia D
    Breast Cancer Res Treat; 2011 Nov; 130(1):207-15. PubMed ID: 21562711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer.
    Vietri MT; Molinari AM; Laura De Paola M; Cantile F; Fasano M; Cioffi M
    Clin Chem Lab Med; 2012 Dec; 50(12):2171-80. PubMed ID: 23096105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.
    Tazzite A; Jouhadi H; Nadifi S; Aretini P; Falaschi E; Collavoli A; Benider A; Caligo MA
    Gynecol Oncol; 2012 Jun; 125(3):687-92. PubMed ID: 22425665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
    Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
    Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
    Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
    Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.